Xeris Q2 ’19 Earnings Update
Yesterday, Xeris published its Q2 ’19 earnings press release highlighting the September 10, 2019 PDUFA for its hypoglycemia rescue product ‘Gvoke.’ Gvoke launch is anticipated in Q4 ’19. Furthermore, the company disclosed utilizing the additional data from the fourth Ph3 trial to file an MAA to EMA by YE 2019. Below, FENIX provides additional thoughts on Gvoke in the context of its additional Ph3 data, and other novel glucagon rescue products.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.